Austin, TX, United States
Austin, TX, United States
SEARCH FILTERS
Time filter
Source Type

PubMed | Osaka University, University of Newcastle, National University of Singapore, University of Manitoba and Lung Therapeutics
Type: Journal Article | Journal: The Journal of allergy and clinical immunology | Year: 2016

Airway smooth muscle (ASM) contraction underpins airway constriction; however, underlying mechanisms for airway hyperresponsiveness (AHR) remain incompletely defined. CD151, a 4-transmembrane glycoprotein that associates with laminin-binding integrins, is highly expressed in the human lung. The role of CD151 in ASM function and its relationship to asthma have yet to be elucidated.We sought to ascertain whether CD151 expression is clinically relevant to asthma and whether CD151 expression affects AHR.Using immunohistochemical analysis, we determined the expression of CD151 in human bronchial biopsy specimens from patients with varying asthma severities and studied the mechanism of action of CD151 in the regulation of ASM contraction and bronchial caliber invitro, exvivo, and invivo.The number of CD151We identify a role for CD151 in human ASM contraction. We implicate CD151 as a determinant of AHR in vivo, likely through regulation of GPCR-induced calcium and PKC signaling. These observations have significant implications in understanding the mechanism for AHR and the efficacy of new and emerging therapeutics.


News Article | February 21, 2017
Site: www.eurekalert.org

Fibrosis investigators at the Medical University of South Carolina show that a caveolin-1 surrogate peptide, known to be anti-fibrotic in the skin and lung, also reverses cardiac fibrosis in a preclinical model Cardiac fibrosis, an abnormal thickening of the heart wall leading to congestive heart failure, was not only halted but also reversed by a caveolin-1 surrogate peptide (CSD) in a preclinical model, report researchers at the Medical University of South Carolina (MUSC) in an article published online on January 23, 2017 by Laboratory Investigation. CSD was able to decrease the fibrotic ventricular wall thickness and improve heart function, all with apparently no toxicity and minimal off-target effects. The MUSC research team included pulmonary fibrosis investigators Stanley Hoffman, Ph.D., and Elena V. Tourkina, Ph.D., who had previously shown caveolin-1's anti-fibrotic properties in the skin and lung. For this project, they joined forces with MUSC congestive heart failure researchers in the laboratory of Dhandapani Kuppuswamy, Ph.D., to show that caveolin-1's anti-fibrotic properties in skin and lung also hold in yet another organ: the heart. More than a decade ago, Hoffman and Tourkina noted that the skin and lung cells producing excess collagen in scleroderma, leading to fibrosis, were deficient in caveolin-1. Supplementing these cells with a caveolin-1 surrogate peptide (CSD; caveolin-1 scaffolding domain peptide), a truncated version of the original compound, showed a reversal of fibrosis. MUSC has obtained a patent to test CSD on fibrotic diseases across organs which they have licensed to Lung Therapeutics, Inc. The company intends to support research involving CSD and fibrosis in the Hoffman and Kuppuswamy laboratories. Kuppuswamy's laboratory focuses on hypertrophic overgrowth and profibrogenic signaling of the cardiac muscle in pressure overload. Fibrosis that develops under these conditions is detrimental to the heart's pumping efficiency as it causes a stiffer and less compliant cardiac muscle, leading to the progression of congestive heart failure. "Currently, there are no therapeutic options for congestive heart failure that specifically target the causative cardiac fibrosis. Everyone is looking for this," said Kuppuswamy, an associate professor at the Gazes Cardiac Research Institute. According to the Centers for Disease Control and Prevention, heart failure affects almost six million Americans, and half of those with heart failure die within five years of diagnosis. To mimic the cardiac fibrosis typical of heart failure, Kuppuswamy used a transverse aortic constriction mouse model to create pressure overload hypertrophy that then led to the development of fibrosis. Treatment with CSD not only halted the progression of the cardiac fibrosis but also led to its reversal with improved ventricular function. Although promising, these findings are preliminary -- only reflecting outcomes in mice. The researchers plan to run larger preclinical studies using the same approach to generate more definitive data, and if all goes as expected, to move forward to the large-animal studies necessary to take a compound forward into clinical trial. They also note that they are testing CSD in a different congestive heart failure model, the angiotensin II infusion model, which also affects the kidneys. CSD is showing promising anti-fibrotic effects on both the heart and the kidneys in this model. "Fibrotic diseases are related to each other no matter the affected organ. In our case, we were studying lung and skin fibrosis," explained Hoffman. "We got the opportunity to test the same reagent in heart fibrosis and, lo and behold, it worked even better than in lung and skin fibrosis models. And there are plenty of other diseases with a fibrotic element to them where we think the CSD peptide might be useful." The co-authors thank the MUSC College of Medicine Enhancement of Team Science (COMETS) for helping support this work. Without this support, this work would not have been possible. Founded in 1824 in Charleston, The Medical University of South Carolina is the oldest medical school in the South. Today, MUSC continues the tradition of excellence in education, research, and patient care. MUSC educates and trains more than 3,000 students and residents, and has nearly 13,000 employees, including approximately 1,500 faculty members. As the largest non-federal employer in Charleston, the university and its affiliates have collective annual budgets in excess of $2.2 billion. MUSC operates a 750-bed medical center, which includes a nationally recognized Children's Hospital, the Ashley River Tower (cardiovascular, digestive disease, and surgical oncology), Hollings Cancer Center (a National Cancer Institute designated center) Level I Trauma Center, and Institute of Psychiatry. For more information on academic information or clinical services, visit musc.edu. For more information on hospital patient services, visit muschealth.org.


NEW YORK, NY / ACCESSWIRE / February 16, 2017 / Small Cap Nation™ (SCN), a New York based financial media and content distribution platform, will host an invitation-only event - The Family Office & Life Science Symposium (the Symposium) - at the NASDAQ MarketSite in New York on Tuesday, February 21, 2017, to connect highly-vetted private and public companies with select family offices and other qualified investors through presentations, one-on-one meetings and other exclusive networking opportunities. "We are very excited to kick off our ongoing 'Best of Breed' series with The Family Office & Life Science Symposium," said Hugh Austin, Chief Executive Officer of SCN. "Through SCN's strong family office and investor network and our access to top-quality companies, we have assembled an excellent roster of presenters and attendees." Confirmed public and private companies who will be presenting at the Symposium, include: AcelRX (NASDAQ: ACRX), Amyris (NASDAQ: AMRS), Cellular Biomedicine Group (NASDAQ: CBMG), Dicerna Pharmaceuticals (NASDAQ: DRNA), Geneius Biotechnology (PRIVATE), Hemispherx Biopharma (NYSE MKT: HEB), Lung Therapeutics (PRIVATE), MYnd Analytics, Inc. (OTCQB: MYAN), Myomo (PRIVATE), PreScience Labs (PRIVATE) and Sensus Healthcare (NASDAQ: SRTS). According to Austin, the use of technology will also play an important role in the Symposium. "We thought a lot about how to best highlight our impressive list of presenting companies, while also creating an unparalleled experience for our investor audience. With that in mind, we'll be providing investor attendees with portable, complimentary tablets pre-loaded with customized presentation material and video content about each of the presenting companies that will be right at the fingertips of prospective investors at the event and after." Additional technology resources will be provided by one of the Symposium's strategic partners, The Trout Group, whose partnering app will be utilized to offer seamless one-on-one meeting scheduling. Other Symposium strategic partners who have provided valuable industry insight and support for the event include: BioInvest, Catalyst, Citigate Dewe Rogerson Ltd, CrowdfundX, Harvest, Investopedia, Investor Torque, Manhattan Capital, Rx Communications Group LLC and Seed Invest. The Symposium's Family Office strategic partners supporting the event include: Family Office Networks, Family Office Insights and Cavendish Global. Media partners who will be covering the Symposium, include: Financial Buzz, Insider Monkey, Internet Stock Review, Ladydrinks, and SnappConner PR. The Symposium will also be broadcast on Facebook Live. The Symposium's program will offer an educational and thought leader component with panels led by host and co-moderator, financial and business journalist, Jane King, and co-moderator Michael J. Levas, Co-Founder, Senior Managing Principal and Chief Investment Officer, Asclepius Life Science Fund, LP. The panels will include top KOL's, research analysts, banking and investment professionals in discussions regarding industry hot topics and key considerations when investing in the life science space. The Family Office Investment Symposium is an ongoing series that identifies superior transition-stage private and public biotech, life science, healthcare and medical technology companies. These highlighted companies are focused on the latest disruptive technologies and relevant industry trends. The SCN symposiums are designed to connect a curated group of highly vetted companies with a carefully selected group of sophisticated investors. Small Cap Nation (www.smallcapnation.com) is a New York based financial media and content distribution platform that develops and delivers breaking, on-demand news and information from our studios at the New York Stock Exchange, and the NASDAQ MarketSite in Times Square. SCN’s focus is on the multi-billion dollar small cap sector, both domestically and internationally. This video-centric programming is distributed across digital channels including social media, broadcast, and newsletters. SCN's distribution consists of a proprietary network of more than 5 million active investors, Funds, Institutions and more than 4000 Family Offices through our strategic alliance with Family Office Networks, Cavendish Global and Family Office Insights. Financial news and trading sites that feature SCN's content include; Harvest Exchange™, Bloomberg, Yahoo Finance, SCN YouTube Channel, StockWatchIndex, FoxBusinessNews, Business Insider, and more. For inquiries regarding Small Cap Nation and The Symposium, please contact:


Confirmed public and private companies who will be presenting at the Symposium, include: AcelRX (NASDAQ: ACRX), Amyris (NASDAQ: AMRS), Cellular Biomedicine Group (NASDAQ: CBMG), Dicerna Pharmaceuticals (NASDAQ: DRNA), Geneius Biotechnology (PRIVATE), Hemispherx Biopharma (NYSE MKT: HEB), Lung Therapeutics (PRIVATE), MYnd Analytics, Inc. (OTCQB: MYAN), Myomo (PRIVATE), PreScience Labs (PRIVATE) and Sensus Healthcare (NASDAQ: SRTS). According to Austin, the use of technology will also play an important role in the Symposium. "We thought a lot about how to best highlight our impressive list of presenting companies, while also creating an unparalleled experience for our investor audience. With that in mind, we'll be providing investor attendees with portable, complimentary tablets pre-loaded with customized presentation material and video content about each of the presenting companies that will be right at the fingertips of prospective investors at the event and after." Additional technology resources will be provided by one of the Symposium's strategic partners, The Trout Group, whose partnering app will be utilized to offer seamless one-on-one meeting scheduling. Other Symposium strategic partners who have provided valuable industry insight and support for the event include: BioInvest, Catalyst, Citigate Dewe Rogerson Ltd, CrowdfundX, Harvest, Investopedia, Investor Torque, Manhattan Capital, Rx Communications Group LLC and Seed Invest. The Symposium's Family Office strategic partners supporting the event include: Family Office Networks, Family Office Insights and Cavendish Global. Media partners who will be covering the Symposium, include: Financial Buzz, Insider Monkey, Internet Stock Review, Ladydrinks, and SnappConner PR. The Symposium will also be broadcast on Facebook Live. The Symposium's program will offer an educational and thought leader component with panels led by host and co-moderator, financial and business journalist, Jane King, and co-moderator Michael J. Levas, Co-Founder, Senior Managing Principal and Chief Investment Officer, Asclepius Life Science Fund, LP. The panels will include top KOL's, research analysts, banking and investment professionals in discussions regarding industry hot topics and key considerations when investing in the life science space. The Family Office Investment Symposium is an ongoing series that identifies superior transition-stage private and public biotech, life science, healthcare and medical technology companies. These highlighted companies are focused on the latest disruptive technologies and relevant industry trends. The SCN symposiums are designed to connect a curated group of highly vetted companies with a carefully selected group of sophisticated investors. Small Cap Nation (www.smallcapnation.com) is a New York based financial media and content distribution platform that develops and delivers breaking, on-demand news and information from our studios at the New York Stock Exchange, and the NASDAQ MarketSite in Times Square. SCN’s focus is on the multi-billion dollar small cap sector, both domestically and internationally. This video-centric programming is distributed across digital channels including social media, broadcast, and newsletters. SCN's distribution consists of a proprietary network of more than 5 million active investors, Funds, Institutions and more than 4000 Family Offices through our strategic alliance with Family Office Networks, Cavendish Global and Family Office Insights. Financial news and trading sites that feature SCN's content include; Harvest Exchange™, Bloomberg, Yahoo Finance, SCN YouTube Channel, StockWatchIndex, FoxBusinessNews, Business Insider, and more. For inquiries regarding Small Cap Nation and The Symposium, please contact:


News Article | November 14, 2016
Site: www.prnewswire.co.uk

ReportsnReports.com adds "Idiopathic Pulmonary Fibrosis - Pipeline Review, H2 2016" to its store providing comprehensive information on the therapeutics under development for Idiopathic Pulmonary Fibrosis (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Complete report on H2 2016 pipeline review of Idiopathic Pulmonary Fibrosis with 78 market data tables and 15 figures, spread across 260 pages is available at http://www.reportsnreports.com/reports/743476-idiopathic-pulmonary-fibrosis-pipeline-review-h2-2016.html . Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal disease characterized by inflammation and scarring of lung tissue and loss of lung function. Symptoms of IPF include dry cough, shortness of breath, especially during or after physical activity, lasting tiredness and weight loss. Risk factors include smoking, environmental exposure, viral infections, family history and abnormal acid reflux. Treatment includes antioxidants, biological response modulators, anti-fibrotic agents and anticoagulants. Companies discussed in this Idiopathic Pulmonary Fibrosis Pipeline Review, H2 2016 report include AdAlta Pty Ltd., Aeolus Pharmaceuticals, Inc., Afferent Pharmaceuticals, Inc., Apellis Pharmaceuticals Inc, ARMO Biosciences, Inc., Asahi Kasei Pharma Corp., Biogen Inc, Bioneer Corporation, BiOrion Technologies B.V., Bristol-Myers Squibb Company, Celgene Corporation, Chrysalis Pharma SAS, Compugen Ltd., Cynata Therapeutics Limited, F. Hoffmann-La Roche Ltd., FibroGen, Inc., FibroStatin SL, Galapagos NV, GenKyoTex S.A., GlaxoSmithKline Plc, Global Blood Therapeutics, Inc., GNI Group Ltd., HEC Pharm Co., Ltd., Histocell S.L., iBio, Inc., Immunomet Therapeutics, Inc., Inventiva, Isarna Therapeutics GmbH, Kadmon Corporation, LLC, Kasiak Research Private Limited, Kolltan Pharmaceuticals, Inc., Kyorin Pharmaceutical Co., Ltd., Lung Therapeutics Inc, Moerae Matrix, Inc., MorphoSys AG, Novartis AG, Nuevolution AB, Pharmaxis Limited, Promedior, Inc., ProMetic Life Sciences Inc., Pulmatrix, Inc., Respira Therapeutics Inc, Ribomic Inc., Saje Pharma, LLC, Samumed LLC, Sanofi Sorrento Therapeutics, Inc., SPR Biosciences LLC, Teva Pharmaceutical Industries Ltd., Therabron Therapeutics, Inc., Vicore Pharma AB and Yuhan Corporation. The Idiopathic Pulmonary Fibrosis (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Idiopathic Pulmonary Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 14, 13, 1, 49 and 8 respectively for Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 4 and 3 molecules, respectively for Idiopathic Pulmonary Fibrosis. Idiopathic Pulmonary Fibrosis (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Another newly published market research report titled Bronchiectasis - Pipeline Review, H2 2016 provides comprehensive information on the therapeutic development for Bronchiectasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bronchiectasis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development are Alitair Pharmaceuticals, Inc., Bayer AG, Grifols, S.A., Insmed Incorporated, Kamada Ltd., Polyphor Ltd., Raptor Pharmaceutical Corp., Recipharm AB, Savara Inc. and Vertex Pharmaceuticals Incorporated. Bronchiectasis Pipeline market research report of 84 pages is available at http://www.reportsnreports.com/reports/743455-bronchiectasis-pipeline-review-h2-2016.html . ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports. Connect With Us on:


Carson J.L.,University of New Brunswick | Terrin M.L.,University of Maryland, Baltimore | Noveck H.,University of New Brunswick | Sanders D.W.,University of Western Ontario | And 14 more authors.
New England Journal of Medicine | Year: 2011

Background: The hemoglobin threshold at which postoperative red-cell transfusion is warranted is controversial. We conducted a randomized trial to determine whether a higher threshold for blood transfusion would improve recovery in patients who had undergone surgery for hip fracture. Methods: We enrolled 2016 patients who were 50 years of age or older, who had either a history of or risk factors for cardiovascular disease, and whose hemoglobin level was below 10 g per deciliter after hip-fracture surgery. We randomly assigned patients to a liberal transfusion strategy (a hemoglobin threshold of 10 g per deciliter) or a restrictive transfusion strategy (symptoms of anemia or at physician discretion for a hemoglobin level of <8 g per deciliter). The primary outcome was death or an inability to walk across a room without human assistance on 60-day follow-up. Results: A median of 2 units of red cells were transfused in the liberal-strategy group and none in the restrictive-strategy group. The rates of the primary outcome were 35.2% in the liberal-strategy group and 34.7% in the restrictive-strategy group (odds ratio in the liberal-strategy group, 1.01; 95% confidence interval [CI], 0.84 to 1.22), for an absolute risk difference of 0.5 percentage points (95% CI, -3.7 to 4.7). The rates of in-hospital acute coronary syndrome or death were 4.3% and 5.2%, respectively (absolute risk difference, -0.9%; 99% CI, -3.3 to 1.6), and rates of death on 60-day follow-up were 7.6% and 6.6%, respectively (absolute risk difference, 1.0%; 99% CI, -1.9 to 4.0). The rates of other complications were similar in the two groups. Conclusions: A liberal transfusion strategy, as compared with a restrictive strategy, did not reduce rates of death or inability to walk independently on 60-day follow-up or reduce in-hospital morbidity in elderly patients at high cardiovascular risk. (Funded by the National Heart, Lung, and Blood Institute; FOCUS ClinicalTrials.gov number, NCT00071032.) Copyright © 2011 Massachusetts Medical Society. All rights reserved.


Bertoncello I.,Lung Therapeutics
Journal of Cellular Physiology | Year: 2016

The last decade has seen significant progress in understanding the organisation of regenerative cells in the adult lung. Cell-lineage tracing and in vitro clonogenic assays have enabled the identification and characterisation of endogenous lung epithelial stem and progenitor cells. Selective lung injury models, and genetically engineered mice have revealed highly conserved gene networks, factors, signalling pathways, and cellular interactions important in maintaining lung homeostasis and regulating lung regeneration and repair following injury. This review describes the current models of lung epithelial stem and progenitor cell organisation in adult mice, and the impediments encountered in translational studies aiming to identify and characterise their human homologs. © 2016 Wiley Periodicals, Inc.


Ferrell B.,Nursing Research and Education | Koczywas M.,Lung Therapeutics | Grannis F.,Thoracic Cancer Program | Harrington A.,Cedars Sinai Medical Center
Surgical Clinics of North America | Year: 2011

Advancements in the surgical and medical treatment of lung cancer have resulted in more favorable short-term survival outcomes. After initial treatment, lung cancer requires continued surveillance and follow-up for long-term side effects and possible recurrence. The integration of quality palliative care into routine clinical care of patients with lung cancer after surgical intervention is essential in preserving function and optimizing quality of life through survivorship. An interdisciplinary palliative care model can effectively link patients to the appropriate supportive care services in a timely fashion. This article describes the role of palliative care for patients with lung cancer. © 2011 Elsevier Inc.


PubMed | Australian National University, La Trobe University and Lung Therapeutics
Type: Journal Article | Journal: Immunology and cell biology | Year: 2016

The MS4A (membrane-spanning 4-domain family, subfamily A) family of proteins contains some well-known members including MS4A1 (CD20), MS4A2 (FcRI) and MS4A3 (HTm4). These three MS4A family members are expressed on the cell surface of specific leukocyte subsets and have been well characterized as having key roles in regulating cell activation, growth and development. However, beyond MS4A1-3 there are a large number of related molecules (18 to date in humans) where our understanding of their biological roles is at a relatively nascent stage. This review examines the larger MS4A family focusing on their structure, expression, regulation and characterized and/or emerging biological roles. Our own work on one family member MS4A8B, and its possible role in epithelial cell regulation, is also highlighted.

Loading Lung Therapeutics collaborators
Loading Lung Therapeutics collaborators